Blood test may guide ovarian cancer maintenance therapy

NCT ID NCT05027828

Recruiting now Knowledge-focused Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test for circulating tumor DNA (ctDNA) can help predict how well PARP inhibitor maintenance therapy works in women with high-grade serous ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, during targeted therapy, and at disease progression. The goal is to see if ctDNA levels can guide treatment decisions and detect recurrence early. The study plans to enroll 100 participants who are newly diagnosed and receiving first-line treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that helps doctors choose the right maintenance therapy for ovarian cancer and catch recurrence earlier.
What could go wrong: This is an observational study, not a treatment trial. It is still recruiting and results may not change practice immediately. The approach may not prove reliable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRCULATING TUMOR DNA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRCULATING TUMOR DNA HIGH GRADE SEROUS OVARIAN CANCER

Contacts and locations

Locations

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.